NDA 204781 · Guerbet
Dotarem
Gadoterate Meglumine · Intravenous
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Mar 5, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Mar 20, 2013
Approved uses
2
Original approval plus efficacy supplements
Registered trials
39
10 Phase 3, 8 recruiting
FAERS reports
3,261
2,312 serious, 64 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS Risk Associated with Intrathecal Use Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. DOTAREM is not approved for intrathecal use [see Warnings and Precautions ( 5.1 )] . Nephrogenic Systemic Fibrosis GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of DOTAREM in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs. The risk for NSF appears highest among patients with: Chronic, severe kidney disease (GFR < 30 mL/min/1.73 m 2 ), or Acute kidney injury....
What it is approved for
From the label in effect Mar 14, 2025.
DOTAREM is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity. DOTAREM is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.
Mechanism: Gadoterate is a paramagnetic molecule that develops a magnetic moment when placed in a magnetic field. The magnetic moment enhances the relaxation rates of water protons in its vicinity, leading to an increase in signal intensity (brightness) of tissues. In magnetic resonance imaging (MRI), visualization of normal and pathological tissue depends in part on variations in the radiofrequency signal intensity that occurs with: differences in proton density differences of the spin-lattice or longitudinal relaxation times (T1) differences in the spin-spin or transverse relaxation time (T2) When...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 25, 2017 Supplement 1 · Efficacy LabelLetterPediatric Clinical Pharmacology Review
- Mar 20, 2013 Original approval · Type 1 - New Molecular Entity · priority review NovelReviewSummary ReviewPediatric Clinical Pharmacology Review
5 products under this application
- DOTAREM · GADOTERATE MEGLUMINE 1.8845GM/5ML (376.9MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
- DOTAREM · GADOTERATE MEGLUMINE 5.6535GM/15ML (376.9MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
- DOTAREM · GADOTERATE MEGLUMINE 37.69GM/100ML (376.9MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
- DOTAREM · GADOTERATE MEGLUMINE 7.538GM/20ML (376.9MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
- DOTAREM · GADOTERATE MEGLUMINE 3.769GM/10ML (376.9MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Gadoterate Meglumine" as an intervention, any sponsor and status, largest first.
GuerbetIndustry
NCT04373564 · 2,076 participants (planned) · Start Mar 24, 2021 · Primary completion Dec 31, 2028
Drug: Gadoxetate disodium; Gadobenate dimeglumine and 4 more · For: Motor Function; Cognitive Function; Contrast Media
Sites: Scottsdale, Arizona; New Haven, Connecticut; Chicago, Illinois · 51 sites in all
- Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) LesionsPivotal-lookingCompleted
GuerbetIndustry
NCT01211873 · 416 participants · Start Sep 2010 · Primary completion Nov 2011
Drug: Dotarem (gadoterate meglumine); Magnevist (gadopentetate dimeglumine) · For: Diagnostic Self Evaluation; Central Nervous System Diseases
Sites: Birmingham, Alabama; Tucson, Arizona; Indian Wells, California · 52 sites in all
- A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)Pivotal-lookingCompleted
BayerBayer (BAYRY)
NCT05915728 · 410 participants · Start Jul 24, 2023 · Primary completion May 31, 2024
Drug: Gadoquatrane (BAY1747846); Gadobutrol and 2 more · For: Contrast Enhancement in Magnetic Resonance Imaging; Non-central Nervous System Pathology
Sites: Birmingham, Alabama; Indian Wells, California; Orange, California · 85 sites in all
GuerbetIndustry
NCT01254552 · 351 participants · Start Aug 2010 · Primary completion Sep 2011
Drug: iobitridol; gadoterate meglumine · For: Type 2 Diabetes Mellitus; Coronary Atherosclerosis
Sites: Seoul, South Korea
- A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related ProblemsPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT05915702 · 321 participants · Start Jul 24, 2023 · Primary completion May 30, 2024
Drug: Gadoquatrane (BAY1747846); Gadobutrol and 2 more · For: Contrast Enhancement in Magnetic Resonance Imaging; Central Nervous System Pathology
Sites: Indian Wells, California; Orange, California; Miami, Florida · 78 sites in all
- Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular DiseasePivotal-lookingRecruiting
GuerbetIndustry
NCT07348640 · 315 participants (planned) · Start Jul 28, 2026 · Primary completion Dec 31, 2027
Drug: gadopiclenol; Gadoterate meglumine (Dotarem) · For: Steno-occlusive Disease
Sites: Birmingham, Alabama; Los Angeles, California; Aurora, Colorado · 43 sites in all
- Dotarem vs Gadobutrol Contrast for Breast MRIPivotal-lookingCompleted
University of Massachusetts, WorcesterAcademic, hospital or other
NCT03730051 · 300 participants · Start Mar 1, 2021 · Primary completion Dec 31, 2025
Drug: Gadoterate meglumine; Gadobutrol · For: Breast Diseases
Sites: Worcester, Massachusetts
- Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain TumorsPivotal-lookingCompleted
GuerbetIndustry
NCT02034708 · 279 participants · Start Jun 2014 · Primary completion Sep 2015
Drug: Dotarem®; Gadovist®/Gadavist® · For: Primary Brain Tumor
Sites: Birmingham, Alabama; Tucson, Arizona; Los Angeles, California · 32 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- urticaria612
- dyspnoea488
- nausea476
- pruritus453
- vomiting384
- erythema376
- cough270
- rash253
- product use in unapproved indication205
- dizziness187
- headache184
- paraesthesia159
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 5 |
| 2011 | 5 |
| 2012 | 7 |
| 2013 | 67 |
| 2014 | 66 |
| 2015 | 221 |
| 2016 | 225 |
| 2017 | 258 |
| 2018 | 395 |
| 2019 | 313 |
| 2020 | 333 |
| 2021 | 264 |
| 2022 | 220 |
| 2023 | 237 |
| 2024 | 239 |
| 2025 | 194 |
| 2026 | 202 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.
Woolen SA, Shankar PR, Gagnier JJ, et al. · JAMA Intern Med 2020 · Meta-Analysis, Systematic Review
- Gadolinium-based contrast: an alternative contrast agent for endovascular interventions.
Parodi JC, Ferreira LM · Ann Vasc Surg 2000 · Clinical Trial
- Increased Signal Intensity in the Dentate Nucleus on Unenhanced T1-Weighted Images After Gadobenate Dimeglumine Administration.
Weberling LD, Kieslich PJ, Kickingereder P, et al. · Invest Radiol 2015 · Controlled Clinical Trial
- Magnetic resonance imaging of the spleen: influence of the dose of a gadolinium chelate on the degree of parenchymal enhancement.
Soyer P, Scherrer A · Acad Radiol 1996 · Clinical Trial, Randomized Controlled Trial
- Can neutrophil gelatinase-associated lipocalin help depict early contrast material-induced nephropathy?
Lacquaniti A, Buemi F, Lupica R, et al. · Radiology 2013 · Randomized Controlled Trial
- Intraindividual, randomized comparison of the macrocyclic contrast agents gadobutrol and gadoterate meglumine in breast magnetic resonance imaging.
Fallenberg EM, Renz DM, Karle B, et al. · Eur Radiol 2015 · Comparative Study, Randomized Controlled Trial
Sponsor: Guerbet
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.